Novo Nordisk didn't find GLP-1s, they commercialized them. The current dean of Harvard medical school says he had a startup on them in the 80's.
A lot of the GLP-1 success is based on progress made in the diabetes space (incidentally so), the refinement of molecules and better understanding of how obesity could be treated.